Macular telangiectasia type 2

[1]  S. Charles,et al.  Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  K. Nishida,et al.  Comparison of macular pigment in three types of macular telangiectasia , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[3]  Ling Zhu,et al.  Conditional Müller Cell Ablation Causes Independent Neuronal and Vascular Pathologies in a Novel Transgenic Model , 2012, The Journal of Neuroscience.

[4]  R. Pappuru,et al.  EFFICACY OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN SUBRETINAL NEOVASCULARIZATION SECONDARY TO MACULAR TELANGIECTASIA TYPE 2 , 2012, Retina.

[5]  R. Venkatesh,et al.  Spontaneous closure of full-thickness macular hole in type 2 idiopathic macular telangiectasia , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[6]  A. Tsujikawa,et al.  RETINAL STRUCTURAL ALTERATIONS AND MACULAR SENSITIVITY IN IDIOPATHIC MACULAR TELANGIECTASIA TYPE 1 , 2012, Retina.

[7]  Catherine Egan,et al.  "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. , 2012, Investigative ophthalmology & visual science.

[8]  G. Hageman,et al.  Ultrastructural and clinical evidence of subretinal debris accumulation in type 2 macular telangiectasia , 2012, British Journal of Ophthalmology.

[9]  A. Bird,et al.  Macular pigment parameters in patients with macular telangiectasia (MacTel) and normal subjects: implications of a novel analysis. , 2012, Investigative ophthalmology & visual science.

[10]  Krzysztof Kiryluk,et al.  Identification of a Potential Susceptibility Locus for Macular Telangiectasia Type 2 , 2012, PloS one.

[11]  Irene Leung,et al.  The Prevalence of Type 2 Idiopathic Macular Telangiectasia in Two African Populations , 2012, Ophthalmic epidemiology.

[12]  Brian C. Toy,et al.  TREATMENT OF NONNEOVASCULAR IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 WITH INTRAVITREAL RANIBIZUMAB: Results of a Phase II Clinical Trial , 2012, Retina.

[13]  G. Hageman,et al.  Pilot application of iTRAQ to the retinal disease Macular Telangiectasia. , 2012, Journal of proteome research.

[14]  H. Oyamada,et al.  Demographic features of idiopathic macular telangiectasia in Japanese patients , 2012, Japanese Journal of Ophthalmology.

[15]  J. Jonas,et al.  Intravitreal bevacizumab for perifoveal telangiectasia , 2011, Acta ophthalmologica.

[16]  Michael D Abramoff,et al.  INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF PROLIFERATIVE AND NONPROLIFERATIVE TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2011, Retina.

[17]  A. Tsujikawa,et al.  High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy. , 2011, Investigative ophthalmology & visual science.

[18]  S. Kang,et al.  Clinical Features of Idiopathic Juxtafoveal Telangiectasis in Koreans , 2011, Korean journal of ophthalmology : KJO.

[19]  F. Holz,et al.  Erratum: Monthly ranibizumab for nonproliferative macular telangiectasia type 2: A 12-month prospective study (American Journal of Ophthalmology (2011) 151:5 (876-886)) , 2011 .

[20]  Peter M. G. Munro,et al.  Basement membrane changes in capillaries of the ageing human retina , 2011, British Journal of Ophthalmology.

[21]  P. Charbel Issa,et al.  Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. , 2011, American journal of ophthalmology.

[22]  R. Guymer,et al.  The longitudinal impact of macular telangiectasia (MacTel) type 2 on vision-related quality of life. , 2011, Investigative ophthalmology & visual science.

[23]  P. Bernstein,et al.  Identification of StARD3 as a lutein-binding protein in the macula of the primate retina. , 2011, Biochemistry.

[24]  D. Shukla.  Evolution and management of macular hole secondary to type 2 idiopathic macular telangiectasia , 2011, Eye.

[25]  M. Gillies,et al.  Submacular DL-alpha-aminoadipic acid eradicates primate photoreceptors but does not affect luteal pigment or the retinal vasculature. , 2011, Investigative ophthalmology & visual science.

[26]  Tunde Peto,et al.  Analysis of candidate genes for macular telangiectasia type 2 , 2010, Molecular vision.

[27]  R. Guymer,et al.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2. , 2010, Ophthalmology.

[28]  Steffen Schmitz-Valckenberg,et al.  Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2. , 2010, Ophthalmology.

[29]  U. Schmidt-Erfurth,et al.  Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2 , 2010, Eye.

[30]  D. Pauleikhoff,et al.  MACULAR TELANGIECTASIA: Patterns of Distribution of Macular Pigment and Response to Supplementation , 2010, Retina.

[31]  M. Yuzawa,et al.  Intravitreal bevacizumab therapy for idiopathic macular telangiectasia , 2010, Japanese Journal of Ophthalmology.

[32]  R. Lira,et al.  Intravitreous ranibizumab as treatment for macular telangiectasia type 2. , 2010, Archives of ophthalmology.

[33]  A. Wenzel,et al.  Bone spicule pigment formation in retinitis pigmentosa: insights from a mouse model , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[34]  H. Flynn,et al.  Surgery for full-thickness macular hole in patients with idiopathic macular telangiectasia type 2. , 2010, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[35]  Ronald Klein,et al.  The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. , 2010, American journal of ophthalmology.

[36]  P. Charbel Issa,et al.  Analysis of glutathione S-transferase Pi isoform (GSTP1) single-nucleotide polymorphisms and macular telangiectasia type 2 , 2010, International Ophthalmology.

[37]  J. Cruysberg,et al.  Patients with Sjögren-Larsson syndrome lack macular pigment. , 2010, Ophthalmology.

[38]  A. Tsujikawa,et al.  Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia , 2010, Eye.

[39]  David Williams,et al.  Retinal crystals in type 2 idiopathic macular telangiectasia. , 2010, Ophthalmology (Rochester, Minn.).

[40]  Robert Finger,et al.  Structure-Function Correlation of the Human Central Retina , 2010, PloS one.

[41]  D. Pauleikhoff,et al.  IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2: DISTRIBUTION OF MACULAR PIGMENT AND FUNCTIONAL INVESTIGATIONS , 2010, Retina.

[42]  C. Kramann,et al.  [Idiopathic macular telangiectasia - follow-up with and without laser photocoagulation]. , 2010, Klinische Monatsblatter fur Augenheilkunde.

[43]  R. Guymer,et al.  THE PREVALENCE ESTIMATES OF MACULAR TELANGIECTASIA TYPE 2: The Melbourne Collaborative Cohort Study , 2010, Retina.

[44]  E. Souied,et al.  Type II Idiopathic Macular Telangiectasia and Soft Confluent Drusen , 2010, European journal of ophthalmology.

[45]  G. Staurenghi,et al.  INTEGRATED CLINICAL EVALUATION OF TYPE 2A IDIOPATHIC JUXTAFOVEOLAR RETINAL TELANGIECTASIS , 2010, Retina.

[46]  Tunde Peto,et al.  Baseline Characteristics of Participants in the Natural History Study of Macular Telangiectasia (MacTel) MacTel Project Report No. 2 , 2010, Ophthalmic epidemiology.

[47]  Hendrik P N Scholl,et al.  Familial asymptomatic macular telangiectasia type 2. , 2009, Ophthalmology.

[48]  C. Pournaras,et al.  Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A , 2009, Acta ophthalmologica.

[49]  V. Mahajan,et al.  A new macular dystrophy with anomalous vascular development, pigment spots, cystic spaces, and neovascularization. , 2009, Archives of ophthalmology.

[50]  N. Osborne,et al.  Cellular signaling and factors involved in Müller cell gliosis: Neuroprotective and detrimental effects , 2009, Progress in Retinal and Eye Research.

[51]  Denise Cunningham,et al.  Fundus autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry. , 2009, American journal of ophthalmology.

[52]  G. Rubin,et al.  STRUCTURAL AND FUNCTIONAL CHANGES OVER TIME IN MacTel PATIENTS , 2009, Retina.

[53]  Frank G. Holz,et al.  Metamorphopsia in patients with macular telangiectasia type 2 , 2009, Documenta Ophthalmologica.

[54]  A. Erginay,et al.  Spectral domain optical coherence tomography in type 2 idiopathic perifoveal telangiectasia. , 2009, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[55]  I. Mantel,et al.  Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[56]  T. Berendschot,et al.  Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. , 2009, Experimental eye research.

[57]  Binxing Li,et al.  Purification and partial characterization of a lutein-binding protein from human retina. , 2009, Biochemistry.

[58]  P. Charbel Issa,et al.  The article by Kovach and Rosenfeld. , 2009, Retina.

[59]  Oscar Yanes,et al.  Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. , 2009, The Journal of clinical investigation.

[60]  Hendrik P N Scholl,et al.  Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. , 2009, Investigative ophthalmology & visual science.

[61]  U. Kellner,et al.  Klinik und Diagnostik der Zapfen-Dystrophien , 2009, Der Ophthalmologe.

[62]  J. Shaw,et al.  Retinal vascular caliber and macular telangiectasia type 2. , 2009, Ophthalmology.

[63]  D. Steel,et al.  Comment on macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia. , 2009 .

[64]  Philip J Rosenfeld,et al.  BEVACIZUMAB (AVASTIN) THERAPY FOR IDIOPATHIC MACULAR TELANGIECTASIA TYPE II , 2009, Retina.

[65]  I. Georgalas,et al.  A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis , 2008, Clinical interventions in aging.

[66]  P. Rosenfeld,et al.  Macular spectral-domain optical coherence tomography in patients with X linked retinoschisis , 2008, British Journal of Ophthalmology.

[67]  Magali Saint-Geniez,et al.  Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.

[68]  Tunde Peto,et al.  The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. , 2008, Investigative ophthalmology & visual science.

[69]  I. Maruko,et al.  Early morphological changes and functional abnormalities in group 2A idiopathic juxtafoveolar retinal telangiectasis using spectral domain optical coherence tomography and microperimetry , 2008, British Journal of Ophthalmology.

[70]  V. Kozousek,et al.  Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis. , 2008, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[71]  M. Burnier,et al.  Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis. , 2008, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[72]  Daniel Barthelmes,et al.  Differential optical densities of intraretinal spaces. , 2008, Investigative ophthalmology & visual science.

[73]  F. Holz,et al.  Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia , 2008, British Journal of Ophthalmology.

[74]  R. Zawadzki,et al.  Retinal morphological changes of patients with X-linked retinoschisis evaluated by Fourier-domain optical coherence tomography. , 2008, Archives of ophthalmology.

[75]  P. Charbel Issa,et al.  A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging , 2008, Acta ophthalmologica.

[76]  H. Scholl,et al.  ABNORMAL MACULAR PIGMENT DISTRIBUTION IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2008, Retina.

[77]  M. Gillies,et al.  Quantitative OCT analysis of idiopathic perifoveal telangiectasia. , 2008, Investigative ophthalmology & visual science.

[78]  J. Cruysberg,et al.  Subclinical changes in the juvenile crystalline macular dystrophy in Sjögren-Larsson syndrome detected by optical coherence tomography. , 2008, Ophthalmology.

[79]  H. Sachs,et al.  Bevacizumab in the treatment of idiopathic macular telangiectasia , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[80]  T. Berendschot,et al.  Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia. , 2008, Investigative ophthalmology & visual science.

[81]  G. Rubin,et al.  Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia. , 2008, Archives of ophthalmology.

[82]  J. F. Arevalo,et al.  LONG-TERM EFFECT OF INTRAVITREAL TRIAMCINOLONE IN THE NONPROLIFERATIVE STAGE OF TYPE II IDIOPATHIC PARAFOVEAL TELANGIECTASIA , 2008, Retina.

[83]  P. Rishi,et al.  Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[84]  Z. Ablonczy,et al.  VEGF modulation of retinal pigment epithelium resistance. , 2007, Experimental eye research.

[85]  A. Lotery,et al.  Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins , 2007, British Journal of Ophthalmology.

[86]  E. Stone,et al.  ABCA4 mutations and discordant ABCA4 alleles in patients and siblings with bull’s-eye maculopathy , 2007, British Journal of Ophthalmology.

[87]  R. Spaide,et al.  Centripetal retinal capillary proliferation in idiopathic parafoveolar telangiectasis , 2007, British Journal of Ophthalmology.

[88]  M. Shanmugam,et al.  Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane , 2007, Indian journal of ophthalmology.

[89]  J. J. Laey,et al.  Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane , 2007, Eye.

[90]  P. Charbel Issa,et al.  Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. , 2007, Ophthalmology.

[91]  P. Charbel Issa,et al.  Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. , 2007, Investigative ophthalmology & visual science.

[92]  B. Takahashi,et al.  Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. , 2007, American journal of ophthalmology.

[93]  David T. Shima,et al.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. , 2007, The American journal of pathology.

[94]  I. Scott,et al.  Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[95]  P. Sieving,et al.  Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants. , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[96]  V. Gabel,et al.  Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[97]  Stefan Schinkinger,et al.  Müller cells are living optical fibers in the vertebrate retina , 2007, Proceedings of the National Academy of Sciences.

[98]  J. Slakter,et al.  FULL-THICKNESS MACULAR HOLE FORMATION IN IDIOPATHIC PARAFOVEAL TELANGIECTASIS , 2007, Retina.

[99]  M. Parodi,et al.  Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[100]  P. Venkatesh,et al.  Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[101]  L. Drolsum,et al.  Iris microhaemangiomas and idiopathic juxtafoveolar retinal telangiectasis. , 2006, Acta ophthalmologica Scandinavica.

[102]  O. M. O. Júnior,et al.  Injeção intravítrea de triancinolona no tratamento da telangiectasia retiniana justafoveolar idiopática , 2006 .

[103]  Alain Gaudric,et al.  Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. , 2006, Archives of ophthalmology.

[104]  E. Rakoczy,et al.  Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization. , 2006, Investigative ophthalmology & visual science.

[105]  Michael D. Ober,et al.  ANECORTAVE ACETATE FOR THE TREATMENT OF IDIOPATHIC PERIFOVEAL TELANGIECTASIA: A Pilot Study , 2006, Retina.

[106]  Z. Kapran,et al.  Optical Coherence Tomography Evaluation of Macular Edema after Intravitreal Triamcinolone Acetonide in Patients with Parafoveal Telangiectasis , 2006, European journal of ophthalmology.

[107]  H. Koizumi,et al.  Morphologic features of group 2A idiopathic juxtafoveolar retinal telangiectasis in three-dimensional optical coherence tomography. , 2006, American journal of ophthalmology.

[108]  Peter Wiedemann,et al.  Müller cells in the healthy and diseased retina , 2006, Progress in Retinal and Eye Research.

[109]  Mauget-Faÿsse Martine,et al.  Optical coherence tomography in tamoxifen retinopathy , 2006, Breast Cancer Research and Treatment.

[110]  R. Danis,et al.  Macular pigment: a review of current knowledge. , 2006, Archives of ophthalmology.

[111]  J. F. Arevalo,et al.  Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[112]  Maciej Wojtkowski,et al.  Retinal assessment using optical coherence tomography , 2006, Progress in Retinal and Eye Research.

[113]  L. Yannuzzi,et al.  Idiopathic Macular Telangiectasia , 2006, Retina.

[114]  Weng Tao,et al.  Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[115]  R. Lakhanpal,et al.  Optical coherence tomography of idiopathic juxtafoveolar telangiectasia. , 2006, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[116]  J. Olson,et al.  Macular hole formation associated with idiopathic parafoveal telangiectasia , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[117]  W. Chan,et al.  Use of intravitreal triamcinolone acetonide injection in unilateral idiopathic juxtafoveal telangiectasis , 2005, Clinical & experimental ophthalmology.

[118]  J. Sahel,et al.  Optical coherence tomography findings in tamoxifen retinopathy. , 2005, American journal of ophthalmology.

[119]  J. Folk,et al.  LONG-TERM JUXTAFOVEAL RETINAL TELANGIECTASIA , 2005, Retina.

[120]  T. Das,et al.  Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis. , 2005, American journal of ophthalmology.

[121]  W. Shen,et al.  Generation of transgenic mice with mild and severe retinal neovascularisation , 2005, British Journal of Ophthalmology.

[122]  S. Fekrat,et al.  Group 2A idiopathic juxtafoveolar retinal telangiectasia in monozygotic twins. , 2005, American journal of ophthalmology.

[123]  Paul S Bernstein,et al.  Identification and Characterization of a Pi Isoform of Glutathione S-Transferase (GSTP1) as a Zeaxanthin-binding Protein in the Macula of the Human Eye* , 2004, Journal of Biological Chemistry.

[124]  Salomon Y. Cohen,et al.  Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. , 2004, American journal of ophthalmology.

[125]  R. Spaide,et al.  Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. , 2004, American journal of ophthalmology.

[126]  A. Morland,et al.  Macular pigments: their characteristics and putative role , 2004, Progress in Retinal and Eye Research.

[127]  R. Kim,et al.  Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. , 2004, American journal of ophthalmology.

[128]  F. Davidorf,et al.  Juxtafoveal telangiectasis-a name change? , 2004, Retina.

[129]  L. Postelmans,et al.  Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. , 2004, American journal of ophthalmology.

[130]  A. Ho,et al.  Idiopathic juxtafoveal telangiectasis in association with celiac sprue. , 2004, Archives of ophthalmology.

[131]  Jose A. Martinez.  Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. , 2003, Archives of ophthalmology.

[132]  Shigeki Hashimoto,et al.  Quantification of metamorphopsia in patients with epiretinal membranes. , 2003, Investigative ophthalmology & visual science.

[133]  Martin Friedlander,et al.  MOUSE MODEL OF SUBRETINAL NEOVASCULARIZATION WITH CHOROIDAL ANASTOMOSIS , 2003, Retina.

[134]  R. Hutchins,et al.  Photodynamic therapy with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis. , 2003, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[135]  D. Sarraf,et al.  West African crystalline maculopathy. , 2003, Archives of ophthalmology.

[136]  B. Garretson,et al.  Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. , 2003, Retina.

[137]  S. Sadda,et al.  Idiopathic parafoveal telangiectasis associated with a foveal pseudovitelliform lesion , 2002, The British journal of ophthalmology.

[138]  Weng Tao,et al.  Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. , 2002, Investigative ophthalmology & visual science.

[139]  W. Hauswirth,et al.  Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. , 2002, Experimental eye research.

[140]  T. Hebert,et al.  Adaptive optics scanning laser ophthalmoscopy. , 2002, Optics express.

[141]  A. Bird,et al.  Clinical variations in assessment of bull's-eye maculopathy. , 2002, Archives of ophthalmology.

[142]  M. Seeliger,et al.  Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[143]  T. Aaberg,et al.  Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. , 2002, Archives of ophthalmology.

[144]  S. Trauzettel-Klosinski.  Reading disorders due to visual field defects: a neuro-ophthalmological view , 2002 .

[145]  M. O'Keefe,et al.  Classification of the spectrum of Coats' disease as subtypes of idiopathic retinal telangiectasis with exudation. , 2001, Acta ophthalmologica Scandinavica.

[146]  T. Aleman,et al.  Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[147]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[148]  J. Cruysberg,et al.  Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjögren-Larsson syndrome. , 2000, American journal of ophthalmology.

[149]  M. T. Bonanomi,et al.  Idiopathic Juxtafoveolar Retinal Telangiectasis: Clinical Pattern in 19 Cases , 2000, Ophthalmologica.

[150]  J. Bausch,et al.  Dose dependency of canthaxanthin crystals in monkey retina and spatial distribution of its metabolites. , 2000, Investigative ophthalmology & visual science.

[151]  G. Virgili,et al.  Bilateral juxtafoveolar telangiectasis in monozygotic twins. , 2000, American journal of ophthalmology.

[152]  L. Lagae,et al.  FAMILIAL SPASTIC PARAPLEGIA AND MACULOPATHY WITH JUXTAFOVEOLAR RETINAL TELANGIECTASIS AND SUBRETINAL NEOVASCULARIZATION , 2000, Retina.

[153]  E. Chew,et al.  Radiation exposure: a new risk factor for idiopathic perifoveal telangiectasis. , 1999, Ophthalmology.

[154]  A. Bird,et al.  Repeated injections of a ciliary neurotrophic factor analogue leading to long-term photoreceptor survival in hereditary retinal degeneration. , 1999, Investigative ophthalmology & visual science.

[155]  D. Park,et al.  Bilateral juxtafoveal telangiectasis in a family. , 1999, Retina.

[156]  C. Gravel,et al.  Intraocular Gene Transfer of Ciliary Neurotrophic Factor Prevents Death and Increases Responsiveness of Rod Photoreceptors in theretinal degeneration slow mouse , 1998, The Journal of Neuroscience.

[157]  M. Lavail,et al.  Protection of mouse photoreceptors by survival factors in retinal degenerations. , 1998, Investigative ophthalmology & visual science.

[158]  M. Lowe,et al.  Laser photocoagulation and glucose metabolism in idiopathic juxtafoveolar retinal telangiectasis. , 1998, Ophthalmic surgery and lasers.

[159]  D. Park,et al.  Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. , 1997, Ophthalmology.

[160]  P. Campochiaro,et al.  Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. , 1997, The American journal of pathology.

[161]  C. Gravel,et al.  Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. , 1997, Human gene therapy.

[162]  J. Bausch,et al.  Occurrence of birefringent retinal inclusions in cynomolgus monkeys after high doses of canthaxanthin. , 1997, Investigative ophthalmology & visual science.

[163]  D. Park,et al.  Fibrovascular tissue in bilateral juxtafoveal telangiectasis. , 1996, Archives of ophthalmology.

[164]  J. Nasemann,et al.  [Idiopathic juxtafoveolar telangiectasis. Long-term follow-up of visual acuity]. , 1995, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[165]  C K Dorey,et al.  In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. , 1995, Investigative ophthalmology & visual science.

[166]  B. Blodi,et al.  Idiopathic juxtafoveolar retinal telangiectasis , 1993 .

[167]  S. Friedman,et al.  Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafoveolar retinal telangiectasis. , 1993, Ophthalmic surgery.

[168]  R. Murphy,et al.  Superficial retinal refractile deposits in juxtafoveal telangiectasis. , 1990, American journal of ophthalmology.

[169]  J. Duvall,et al.  Lamellar macular hole associated with idiopathic juxtafoveolar telangiectasia. , 1988, The British journal of ophthalmology.

[170]  A. Bird,et al.  Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. , 1987, Brain : a journal of neurology.

[171]  M. Klein,et al.  Abnormal glucose metabolism and parafoveal telangiectasia. , 1986, American journal of ophthalmology.

[172]  A. Bird,et al.  Retinal telangiectasis in facioscapulohumeral muscular dystrophy with deafness. , 1985, Archives of ophthalmology.

[173]  D M Snodderly,et al.  The macular pigment. I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. , 1984, Investigative ophthalmology & visual science.

[174]  F. Delori,et al.  The macular pigment. II. Spatial distribution in primate retinas. , 1984, Investigative ophthalmology & visual science.

[175]  J. Gass,et al.  Idiopathic juxtafoveolar retinal telangiectasis. , 1982, Archives of ophthalmology.

[176]  W. Green,et al.  Parafoveal retinal telangiectasis: Light and electron microscopy studies , 1980, Transactions of the ophthalmological societies of the United Kingdom.

[177]  D. Fuller,et al.  Focal parafoveal retinal telangiectasis. , 1978, Archives of ophthalmology.

[178]  A. Chopdar.  Retinal telangiectasis in adults: fluorescein angiographic findings and treatment by argon laser. , 1978, The British journal of ophthalmology.

[179]  C. Clemente.  HISTOLOGY OF THE HUMAN EYE : An Atlas and Textbook , 1973 .

[180]  D. Worthen,et al.  Histology of the Human Eye. , 1972 .

[181]  H. Gerrits,et al.  The filling-in process in patients with retinal scotomata. , 1969, Vision research.

[182]  J. Gass.  A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. V. Retinal telangiectasis. , 1968, Archives of ophthalmology.

[183]  J. Gass.  A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. VI. X-ray irradiation, carotid artery occlusion, collagen vascular disease, and vitritis. , 1968, Archives of ophthalmology.

[184]  A. B. Reese,et al.  Telangiectasis of the retina and Coats' disease. , 1956, American journal of ophthalmology.

[185]  Lien Delaere,et al.  Vertical transmission of macular telangiectasia type 2. , 2012, Retinal cases & brief reports.

[186]  L. Yannuzzi,et al.  Peculiar manifestation of macular telangiectasia type 2. , 2011, Retinal cases & brief reports.

[187]  L. Yannuzzi.  The retinal atlas , 2010 .

[188]  P. Massin,et al.  Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia , 2009, Eye.

[189]  P. Charbel Issa,et al.  Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. , 2008, American journal of ophthalmology.

[190]  B. J. Klevering,et al.  Analysis of visual pigment by fundus autofluorescence. , 2008, Experimental eye research.

[191]  A. Bird,et al.  Macular pigment in the human retina: histological evaluation of localization and distribution , 2008, Eye.

[192]  V. Arshavsky,et al.  Progress in Retinal and Eye Research , 2008 .

[193]  P. Charbel Issa,et al.  Short-term effects of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. , 2007, Retinal cases & brief reports.

[194]  F. Recchia,et al.  Neurosensory macular detachment in group 2a juxtafoveolar telangiectasis and resolution following intravitreal triamcinolone. , 2007, Retinal cases & brief reports.

[195]  M. Gillies,et al.  A case of idiopathic perifoveal telangiectasia preceded by features of cone dystrophy , 2007, Eye.

[196]  M. Potter,et al.  Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis. , 2006, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[197]  Atul K. Jain,et al.  Crystalline retinopathies. , 2006, Survey of ophthalmology.

[198]  M. Shanmugam,et al.  RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. , 2005, Indian journal of ophthalmology.

[199]  J. Gass.  Juxtafoveal telangiectasis-a name change? , 2005, Retina.

[200]  M. Potter,et al.  Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. , 2002, American journal of ophthalmology.

[201]  S. Harding.  Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5 , 2002 .

[202]  W. Green,et al.  Histopathologic study of presumed parafoveal telangiectasis. , 1999, Retina.

[203]  N. Bressler.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .

[204]  P. Campochiaro,et al.  Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. , 1998, Investigative ophthalmology & visual science.

[205]  G. Brown,et al.  Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. , 1997, Retina.

[206]  I. McAllister,et al.  Familial idiopathic juxtafoveolar retinal telangiectasis , 1996, Eye.

[207]  B. L. Lee.  Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis. , 1996, Retina.

[208]  J. Nasemann,et al.  Idiopathische juxtafoveoläre Teleangiektasien. Langzeitverlauf des Sehvermögens. , 1995 .

[209]  A. Mansour,et al.  Foveal avascular zone in idiopathic juxtafoveolar telangiectasia. , 1993, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[210]  A. Bird,et al.  Paramacular telangiectasis. , 1986, Transactions of the ophthalmological societies of the United Kingdom.

[211]  E. Chew,et al.  Parafoveal telangiectasis and diabetic retinopathy. , 1986, Archives of ophthalmology.

[212]  Y. Taniguchi,et al.  Retinal vascular patterns in the macula and the perimacular area in premature and full-term infants. , 1982, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[213]  Hogan,et al.  Histology of the human eye;: An atlas and textbook , 1971 .